Manager × security

FARALLON CAPITAL MANAGEMENT LLC BBIO holdings history

Who else holds this security? →

BRIDGEBIO PHARMA INC · CUSIP 10806X102 · CIK 909661

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, FARALLON CAPITAL MANAGEMENT LLC reported 10.74M BBIO (shares), valued at $800.14M, or 4.68% of its reported non-derivative portfolio. Filed 2026-08-14.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
4.68%
Shares
10.74M
10,743,063
Reported value
$800.14M
USD

Shares increased 14.71%; reported value increased 15.05%, and weight changed +0.56 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20264.68%10,743,063SEC filing ↗Filed Aug 14, 2026
Q1 20264.12%9,365,463SEC filing ↗Filed May 15, 2026Amended
Q4 20253.58%8,998,463SEC filing ↗Filed Feb 17, 2026Amended
Q3 20252.40%8,192,000SEC filing ↗Filed Feb 17, 2026Amended
Q2 20251.56%7,900,000SEC filing ↗Filed Aug 14, 2025Amended
Q1 20251.07%5,731,000SEC filing ↗Filed May 15, 2025Amended
Q4 20240.61%4,195,000SEC filing ↗Filed Feb 14, 2025Amended
Q3 20240.24%1,747,000SEC filing ↗Filed Nov 14, 2024Amended
Q2 2024Not reportedNot reported—
Q1 2024Not reportedNot reported—
Q4 20230.00%6,000SEC filing ↗Filed Feb 14, 2024Amended

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q4 20230.00%6,000$242.22KThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Feb 14, 2024
Q1 2024Not reported——This security is absent from this quarter's filing; a missing record is not treated as zero holdings.—
Q2 2024Not reported——This security is absent from this quarter's filing; a missing record is not treated as zero holdings.—
Q3 20240.24%1,747,000$44.48MA comparable prior-quarter record is unavailable; changes are not inferred.SEC filing ↗
Filed Nov 14, 2024
Q4 20240.61%4,195,000$115.11MShares increased 140.13%; reported value increased 158.80%, and weight changed +0.37 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2025
Q1 20251.07%5,731,000$198.12MShares increased 36.62%; reported value increased 72.11%, and weight changed +0.46 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2025
Q2 20251.56%7,900,000$341.12MShares increased 37.85%; reported value increased 72.18%, and weight changed +0.49 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2025
Q3 20252.40%8,192,000$425.49MShares increased 3.70%; reported value increased 24.73%, and weight changed +0.84 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 17, 2026
Q4 20253.58%8,998,463$688.29MShares increased 9.84%; reported value increased 61.76%, and weight changed +1.18 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 17, 2026
Q1 20264.12%9,365,463$695.48MShares increased 4.08%; reported value increased 1.04%, and weight changed +0.54 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2026
Q2 20264.68%10,743,063$800.14MShares increased 14.71%; reported value increased 15.05%, and weight changed +0.56 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2026
FARALLON CAPITAL MANAGEMENT LLC · BRIDGEBIO PHARMA INC

Take these holdings further.

This page includes 11 of 11 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"909661","quarter":"2026Q2","cusip":"10806X102"}

get_institutional_manager_history
{"cik":"909661","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.